Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis

BACKGROUND: Surrogate endpoints (SEs), such as progression-free survival (PFS) and objective response rate (ORR), are frequently used in clinical trials. The relationship between SEs and overall survival (OS) has not been well described in metastatic urothelial cancer (MUC). OBJECTIVE: We evaluated...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Ghali, Fady, Zhao, Yibai, Patel, Devin, Jewell, Teresa, Yu, Evan Y., Grivas, Petros, Montgomery, R. Bruce, Gore, John L., Etzioni, Ruth B., Wright, Jonathan L.
Formatua: Online Artikulua Texto
Hizkuntza:English
Argitaratua: Elsevier 2022
Gaiak:
Bladder Cancer
Sarrera elektronikoa:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806712/
https://www.ncbi.nlm.nih.gov/pubmed/36601043
http://dx.doi.org/10.1016/j.euros.2022.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806712/
https://www.ncbi.nlm.nih.gov/pubmed/36601043
http://dx.doi.org/10.1016/j.euros.2022.11.003

Antzeko izenburuak